Newsroom

Learn about Gb Sciences' research developments, patents, and emerging drug discoveries.

2023
2022
2021

2023

GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China

According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.

Successful 2022 Milestones Support Value of Gb Sciences’ AI-Enabled Drug Discovery Platform

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2023 and key developments from 2022

2022

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

Gb Sciences’ innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.

Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations

As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.

Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients

As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm’s sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.

TODAY: Gb Sciences’ President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit

At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences’ proprietary PhAROS drug discovery platform.

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Gb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

TODAY: Gb Sciences’ President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference

Dr. Andrea Small-Howard discusses the company’s novel process for developing disease-specific, cannabinoid-based therapeutics.

Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson’s Disease

As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm’s sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson’s disease symptoms

TODAY: Gb Sciences Describes Drug Development Progress in Pharma’s Almanac Journal Article

Gb Sciences is focusing considerable resources on bringing its lead Parkinson’s disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.

TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit

President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform’s utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences’ future successes.

Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™

As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it’s already ahead of the curve with its own revolutionary technology.

TODAY: Gb Sciences’ President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson’s Disease at 2022 NeuroForum Summit

Dr. Andrea Small-Howard explains that Gb Sciences’ multicomponent Parkinson’s disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are more effective when used together than singularly, as demonstrated in an animal model of the disease.

TODAY: Gb Sciences’ Novel Plant-Inspired Pain Medications Featured at SMi’s 22nd Annual Pain Therapeutics Conference

President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-based pain medications.

FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences’ COVID-19-Related, Anti-Inflammatory Therapies

Plant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release syndrome.

Gb Sciences to Begin Dosage Study for Its Novel Parkinson’s Disease Formulations at the University of Lethbridge

Biopharmaceutical research company’s plant-inspired formulations entering final stages before first-in-human clinical trials

Gb Sciences’ Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article

On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences’ proprietary, time-released, oral nanoparticle technology improved the efficacy of cannabis-based terpenes in modulating a known pain receptor in this study.

Gb Sciences Issues Shareholder Letter

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021

Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis

This new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.

Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment

Gb Sciences’ collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines ‘Cannabis Business Times’ and ‘Hemp Grower’

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

The sale will accelerate the development of Gb Sciences’ proprietary Parkinson’s disease and COVID-related Cytokine-Release Syndrome therapies

2021

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

Biopharmaceutical research company leverages positive data on its cannabinoid-containing mixtures to develop new cytokine release syndrome therapies

Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships

Biopharmaceutical research company pursues faster route for drug discovery using PhAROS™, Gb Sciences’ AI-enabled drug discovery platform, and through efficiency in their drug development pipeline leveraging strong relationships

Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety

The biopharma technology company’s AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.

Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation

Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences’ preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with COVID-19 and other life-threatening inflammatory conditions.

Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright’s 23rd Annual Global Investment Conference

Highlighting Gb Sciences’ Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson’s Disease during the Healthcare & Biotech Track starting Monday, September 13.
Facebook Twitter Linkedin Youtube